Yoshitomo Kushima1,2
Yasuo Shimizu1*
Ryo Arai1Kazuyuki Chibana1Yuka Shimizu1,3Masahiro Amagai3
Akihiro Takemasa1Naoya Ikeda1Meitetsu Masawa1Atsushi Kushima2Hiroaki Okutomi1
Yusuke Nakamura1Rinna Tei1Yuki Ando1Nana Yazawa1Yuto Goto1
Yasuo Haruyama4Tatsuo Yukawa5
Seiji Niho1
- 1Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Mibu, Tochigi, Japan
- 2Kushima Internal Medicine Clinic, Moka, Tochigi, Japan
- 3Amagai Internal Medicine Clinic, Tochigi, Tochigi, Japan
- 4Integrated Research Faculty for Advanced Medical Sciences, Dokkyo Medical University, Tochigi, Japan
- 5Yukawa Clinic of Internal Medicine, Utsunomiya, Tochigi, Japan
A Correction on
By Kushima Y, Shimizu Y, Arai R, Chibana K, Shimizu Y, Amagai M, Takemasa A, Ikeda N, Masawa M, Kushima A, Okutomi H, Nakamura Y, Tei R, Ando Y, Yazawa N, Goto Y, Haruyama Y, Yukawa T and Niho S (2025). Front. Allergy 6:1537501. doi: 10.3389/falgy.2025.1537501
In the published article, there was an error. There was an incorrect description of statistical methods.
A correction has been made to section 1.4 Statistical analysis, paragraph number 2. This sentence previously stated:
“Changes over time between groups were evaluated by repeated measures, and comparisons of the parameters between the baseline and each time point were evaluated using the Bonferroni method.”
The corrected sentence appears below:
“Changes over time between groups were evaluated by repeated measures, and comparisons of the parameters between the baseline and each time point were evaluated using the Least significant difference (LSD) method.”
In the published article, there was an error in the legend for Figure 2 as published. There was an incorrect description of statistical methods.
The sentence previously stated:
“The bars represent the 95% CI, p-values are for repeated measurements within a group, and the Bonferroni method was used for time comparisons.”
The corrected sentence appears below:
“The bars represent the 95% CI, p-values are for repeated measurements within a group, and the Least significant difference (LSD) method was used for time comparisons.”
In the published article, there was an error in Figure 3C as published. There was an incorrect description of the ratio for patients in the right-side pie chart for the value under “Well n = 10”. The value 10% was corrected to 48%. The corrected figure appears below.
Figure 3. ACT scores and the changes in patients after switching to 100–62.5-25 µg of FF-UMEC-VI (T100 group) (A), 200–62.5-25 µg of FF-UMEC-VI (T200 group) (B) Combined T100 and T200 group data for ACT scores before and after switching to FF-UMEC-VI (C) Patients with ACT scores of <20 before starting FF-UMEC-VI were defined as having poor control, patients with ACT scores of ≥20 and ≤24 before starting FF-UMEC-VI were defined as having good control, and a score of 25 was defined as total control. FF-UMEC-VI, fluticasone furoate-umeclidinium-vilanterol; ACT, asthma control test.
The original article has been updated.
Generative AI statement
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: asthma, cognition, fluticasone furoate, forced expiratory flow volume, trelegy, triple therapy, umeclidinium, vilanterol
Citation: Kushima Y, Shimizu Y, Arai R, Chibana K, Shimizu Y, Amagai M, Takemasa A, Ikeda N, Masawa M, Kushima A, Okutomi H, Nakamura Y, Tei R, Ando Y, Yazawa N, Goto Y, Haruyama Y, Yukawa T and Niho S (2025) Correction: Real-life effectiveness of once-daily single-inhaler triple therapy (FF-UMEC-VI) after switching from dual therapy (ICS-LABA) in patients with symptomatic asthma: trelegy ellipta for real asthma control study. Front. Allergy 6:1683768. doi: 10.3389/falgy.2025.1683768
Received: 11 August 2025; Accepted: 3 September 2025;
Published: 23 September 2025.
Edited and Reviewed by: Kosisochi Amorha, University of Nigeria, Nsukka, Nigeria
Copyright: © 2025 Kushima, Shimizu, Arai, Chibana, Shimizu, Amagai, Takemasa, Ikeda, Masawa, Kushima, Okutomi, Nakamura, Tei, Ando, Yazawa, Goto, Haruyama, Yukawa and Niho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yasuo Shimizu, eWFzdW8tc0Bkb2treW9tZWQuYWMuanA=